Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback